The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor

Antiviral Therapy - United Kingdom
doi 10.3851/imp2773
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Medical Press

Related search

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Journal of Clinical Pharmacology
Pharmacology
2018English

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Evacetrapib

European Journal of Clinical Pharmacology
MedicinePharmacology
2016English

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2020English

Synthesis of HCV Protease Inhibitor MK-6325

Synfacts
2015English

Physical Properties and Biological Activity of Some Novel HCV NS3 Protease Inhibitors

Egyptian Journal of Physics
2018English

Influence of Mild and Moderate Hepatic Impairment on Axitinib Pharmacokinetics

Investigational New Drugs
OncologyPharmacology
2010English

Correlation Between Efficacy of Daclatasvir/Asunaprevir Combination Therapy and HCV NS3/NS5A Resistance-Associated Variants Detected by the PCR-Invader Assay

Acta Hepatologica Japonica
Hepatology
2015English

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib

Journal of Clinical Pharmacology
Pharmacology
2020English

Effect of Famotidine on the Pharmacokinetics of Apixaban, an Oral Direct Factor Xa Inhibitor

Clinical Pharmacology: Advances and Applications
Pharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy